Related Experiment Video
Updated: Apr 29, 2026
11:35
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
58.9K
[Cost of multiple sclerosis in France]
A Fromont1, M-N Lehanneur2, F Rollot3
1Service de neurologie, CHU de Dijon, 3, rue du Faubourg-Raines, 21000 Dijon, France; EA 4184, centre d'épidémiologie des populations, 1, boulevard Jeanne-d'Arc, BP 1542, 21079 Dijon, France.
Revue Neurologique
|May 27, 2014
Summary
Multiple sclerosis (MS) costs French healthcare over €469 million annually, with significant regional variations. The economic burden, including indirect costs, is substantial, comparable to HIV.
Area of Science:
- Neurology
- Health Economics
Context:
- Multiple sclerosis (MS) is a chronic condition designated as a long-term disease (ALD) in France.
- The French national health insurance fund (CNAMTS) covers healthcare costs for 87% of the population.
- This study analyzes the economic impact of MS within the CNAMTS-insured population in 2004.
Purpose:
- To evaluate the direct and indirect medical costs associated with multiple sclerosis in France.
- To determine the cost per patient and per expenditure item for MS.
- To analyze cost variations across French regions and over the disease's progression.
Summary:
- In 2004, 49,413 MS patients incurred direct costs of €469.7 million (€9,506 per patient).
- Expenditures included treatments (44.5%), hospitalization (27.9%), and nursing care (5.8%).
- Indirect costs were estimated at €116 million, with disability pensions and daily allowances impacting numerous patients.
Impact:
- MS imposes a significant economic burden on the French healthcare system, comparable to HIV.
- Costs escalate significantly in the final year of life and vary regionally.
- Understanding these costs informs resource allocation and healthcare policy for chronic diseases.
